Citations (168)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (32)
Kyle P. Martin, Christine Grimaldi, Rolf Grempler, Steven Hansel & Sandeep Kumar. (2023) Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics. mAbs 15:1.
Read now
Read now
Yu Wang, Meng Zhang, Yixin Gong, Qiyan Wu, Lijun Zhang & Shunchang Jiao. (2021) Bioinformatic Analysis of Hepatocellular Carcinoma Cell Lines to the Efficacy of Nimotuzumab. International Journal of General Medicine 14, pages 2611-2621.
Read now
Read now
Pei-Hua Lin, Chi-Ling Tseng, Yun-Chih Cheng, Chieh-Hsin Ho, Shih Chieh Chen, Yanling Wang, Eugene Liu, Hassan Issafras & Weidong Jiang. (2021) Distinguishing features of a novel humanized anti-EGFR monoclonal antibody based on cetuximab with superior antitumor efficacy. Expert Opinion on Biological Therapy 21:11, pages 1491-1507.
Read now
Read now
Shikhar kumar, Vanita Noronha, Vijay Patil, Amit Joshi, Nandini Menon & Kumar Prabhash. (2021) Advances in pharmacotherapy for head and neck cancer. Expert Opinion on Pharmacotherapy 22:15, pages 2007-2018.
Read now
Read now
Chengwei Peng & Deirdre J. Cohen. (2021) Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma. Expert Opinion on Pharmacotherapy 22:1, pages 93-107.
Read now
Read now
Hiroshi Imazeki & Ken Kato. (2020) Development of chemotherapeutics for unresectable advanced esophageal cancer. Expert Review of Anticancer Therapy 20:12, pages 1083-1092.
Read now
Read now
ShishuKant Suman, Rashmi Priya & Mythili Kameswaran. (2020) Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of 177Lu-Nimotuzumab. International Journal of Radiation Biology 96:9, pages 1144-1156.
Read now
Read now
Xue-Song Sun, Yu-Jing Liang, Xiao-Yun Li, Sai-Lan Liu, Qiu-Yan Chen, Lin-Quan Tang & Hai-Qiang Mai. (2019) Palliative chemotherapy with or without anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma: a propensity score-matching study. Drug Design, Development and Therapy 13, pages 3207-3216.
Read now
Read now
Farzaneh Barkhordari, Nooshin Sohrabi, Fatemeh Davami, Fereidoun Mahboudi & Yeganeh Talebkhan Garoosi. (2019) Cloning, expression and characterization of a HER2-alpha luffin fusion protein in Escherichia coli. Preparative Biochemistry & Biotechnology 49:8, pages 759-766.
Read now
Read now
Puey Ling Chia, Andrew M. Scott & Thomas John. (2019) Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma. Expert Opinion on Drug Delivery 16:4, pages 441-451.
Read now
Read now
Arsham Banisadr, Yaghoub Safdari, Anvarsadat Kianmehr & Mahdieh Pourafshar. (2018) Production of a germline-humanized cetuximab scFv and evaluation of its activity in recognizing EGFR- overexpressing cancer cells. Human Vaccines & Immunotherapeutics 14:4, pages 856-863.
Read now
Read now
Jianfeng Huang, Qinzhou Zou, Danqi Qian, Leyuan Zhou, Bo Yang, Jianjun Chu, Qingfeng Pang, Kewei Wang & Fuzheng Zhang. (2017) Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma. OncoTargets and Therapy 10, pages 5835-5841.
Read now
Read now
Alex Françoso & Patricia Ucelli Simioni. (2017) Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies. Drug Design, Development and Therapy 11, pages 177-184.
Read now
Read now
Héctor Vázquez-Becerra, Enrique Pérez-Cárdenas, Saé Muñiz-Hernández, Vanessa Izquierdo-Sánchez & Luis Alberto Medina. (2017) Characterization and in vitro evaluation of nimotuzumab conjugated with cisplatin-loaded liposomes. Journal of Liposome Research 27:4, pages 274-282.
Read now
Read now
Chunyu Wang, Xiaolong Fu, Xuwei Cai, Xianghua Wu, Xichun Hu, Min Fan, Jiaqing Xiang, Yawei Zhang, Haiquan Chen, Guoliang Jiang & Kuaile Zhao. (2016) High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy. OncoTargets and Therapy 9, pages 117-122.
Read now
Read now
Nicholas P. Campbell, Thomas A. Hensing, Mihir K. Bhayani, Arif Y. Shaikh & Bruce E. Brockstein. (2016) Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Expert Review of Anticancer Therapy 16:8, pages 847-858.
Read now
Read now
Olgun Elicin & Mahmut Ozsahin. (2016) Current Role of Dacomitinib in Head and Neck Cancer. Expert Opinion on Investigational Drugs 25:6, pages 735-742.
Read now
Read now
Yun Yang, Qingcheng Guo, Xi Chen, Junjie Zhang, Huaizu Guo, Weizhu Qian, Sheng Hou, Jianxin Dai, Bohua Li, Yajun Guo & Hao Wang. (2016) Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy. mAbs 8:2, pages 405-413.
Read now
Read now
Rui-ping Zhai, Hong-mei Ying, Fang-fang Kong, Cheng-run Du, Shuang Huang, Jun-jun Zhou & Chao-su Hu. (2015) Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. OncoTargets and Therapy 8, pages 3383-3390.
Read now
Read now
Kai Teng, Yong Zhang, Xiaoyan Hu, Yihui Ding, Rui Gong & Li Liu. (2015) Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repair. OncoTargets and Therapy 8, pages 809-818.
Read now
Read now
Qun-ying Yang, Cheng-cheng Guo & Zhong-ping Chen. (2015) Profile of nimotuzumab in the treatment of high-grade glioma. OncoTargets and Therapy 8, pages 819-825.
Read now
Read now
Shivani Mittal, Shrikant Pradhan & Tapasya Srivastava. (2015) Recent advances in targeted therapy for glioblastoma. Expert Review of Neurotherapeutics 15:8, pages 935-946.
Read now
Read now
Dominik Horn, Jochen Hess, Kolja Freier, Jürgen Hoffmann & Christian Freudlsperger. (2015) Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma. Expert Opinion on Therapeutic Targets 19:6, pages 795-805.
Read now
Read now
Yihui Wen & Jennifer R Grandis. (2015) Emerging drugs for head and neck cancer. Expert Opinion on Emerging Drugs 20:2, pages 313-329.
Read now
Read now
Yun Yang, Qingcheng Guo, Mao Xia, Yantao Li, Xiaoyun Peng, Tao Liu, Xin Tong, Jin Xu, Huaizu Guo, Weizhu Qian, Sheng Hou, Jianxin Dai, Hao Wang, Rong Liu & Yajun Guo. (2015) Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency. mAbs 7:2, pages 440-450.
Read now
Read now
Jun Liang, Mingyan E, Gang Wu, Lujun Zhao, Xia Li, Xia Xiu, Ning Li, Bo Chen, Zhouguang Hui, Jima Lv, Hui Fang, Yu Tang, Nan Bi, Wenqing Wang, Yirui Zhai, Tao Li, Dongfu Chen, Shuangmei Zou, Ning Lu, Rolando Perez-Rodríguez, Junqi Zheng & Luhua Wang. (2013) Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial. OncoTargets and Therapy 6, pages 1589-1596.
Read now
Read now
Arlhee Diaz-Miqueli & Giselle Saurez Martinez. (2013) Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities. OncoTargets and Therapy 6, pages 931-942.
Read now
Read now
Udo Bode, Maura Massimino, Ferdinand Bach, Martina Zimmermann, Elena Khuhlaeva, Manfred Westphal & Gudrun Fleischhack. (2012)
Nimotuzumab treatment of malignant gliomas. Expert Opinion on Biological Therapy 12:12, pages 1649-1659.
Read now
Read now
Janice M. Reichert. (2012) Marketed therapeutic antibodies compendium. mAbs 4:3, pages 413-415.
Read now
Read now
Giorgos Papaspyrou, Jochen A Werner & Andreas Dietz. (2011) Pharmacotherapy for squamous-cell carcinoma of the head and neck. Expert Opinion on Pharmacotherapy 12:3, pages 397-409.
Read now
Read now
Janice M. Reichert. (2011)
Antibody-based therapeutics to watch in 2011
. mAbs 3:1, pages 76-99.
Read now
Read now
William Boland & Gwyn Bebb. (2010) The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics: Targets and Therapy 4, pages 289-298.
Read now
Read now
Articles from other publishers (136)
S. Chemmalar, A. R. Intan Shameha, Che Azurahanim Che Abdullah, Nor Asma Ab Razak, Loqman Mohamad Yusof, Mokrish Ajat, Kim Wei Chan & Md Zuki Abu Bakar Zakaria. (2023) Busting the Breast Cancer with AstraZeneca’s Gefitinib. Advances in Pharmacological and Pharmaceutical Sciences 2023, pages 1-26.
Crossref
Crossref
Xue Meng, Anping Zheng, Jun Wang, Xiaoyuan Wu, Guang Li, Jun Zhu, Hu Ma, Xiaodong Zhu, Anhui Shi, Chunhua Dai, Senxiang Yan, Buhai Wang, Zhongyu Qu, Chun Han, Xindong Sun, Ming Ye, Ruitai Fan, Niyazi Huerxidan, Xiaohong Wang & Jinming Yu. (2023) Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial. British Journal of Cancer 129:11, pages 1787-1792.
Crossref
Crossref
Yuesheng Zhang. (2023) Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor. Pharmacological Reviews 75:6, pages 1218-1232.
Crossref
Crossref
Satyam Singh, Sushabhan Sadhukhan & Avinash Sonawane. (2023) 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1878:6, pages 188967.
Crossref
Crossref
Xiaoyan Xu, Hengzhao Zhuang, Yijun Xu, Zhongxu Xing, Yang Jiao & Lili Wang. (2023) Advances of radiotherapy combined with targeted therapy for nasopharyngeal carcinoma. Radiation Medicine and Protection.
Crossref
Crossref
Arash Letafati, Omid Salahi Ardekani, Mina Naderisemiromi, Mohammad Mehdi Fazeli, Nillofar Asadi Jemezghani & Jila Yavarian. (2023) Oncolytic viruses against cancer, promising or delusion?. Medical Oncology 40:8.
Crossref
Crossref
Rui Zhang, Pengfei Pei, Yifan Wang, Quanqiang Guo, Shi‐Zhong Luo & Long Chen. (2023)
A single‐chain variable fragment‐anticancer lytic peptide (
scFv‐ACLP
) fusion protein for targeted cancer treatment
. Chemical Biology & Drug Design 101:6, pages 1406-1415.
Crossref
Crossref
Amirhossein Tamimi, Atena Tamimi, Fatemeh Sorkheh, Saba Mardekatani Asl, Arezoo Ghafari, Arian Ghannadi Karimi, Gisou Erabi, Hossein Pourmontaseri & Niloofar Deravi. (2023) Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. Cancer Reports 6:5.
Crossref
Crossref
Swati Sharma, Rashmi Rana, Prem Prakash & Nirmal Kumar Ganguly. (2023) Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors. Molecular and Cellular Biochemistry.
Crossref
Crossref
Xin Huang, Shuyou Shi, Hongrui Wang, Tiesuo Zhao, Yibo Wang, Sihua Huang, Yingying Su, Chunyan Zhao & Ming Yang. (2023) Advances in antibody-based drugs and their delivery through the blood-brain barrier for targeted therapy and immunotherapy of gliomas. International Immunopharmacology 117, pages 109990.
Crossref
Crossref
Longchao Liu & Jiahui Chen. (2023) Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. Medical Review 2:6, pages 555-569.
Crossref
Crossref
James J. Kang, Albert Ko, Sang Hoon Kil, Jon Mallen-St. Clair, Daniel Sanghoon Shin, Marilene B. Wang & Eri S. Srivatsan. (2023) EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1878:1, pages 188827.
Crossref
Crossref
Tian Li, Wenyan Fu, Changhai Lei & Shi Hu. 2023. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies. Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies
1
12
.
Jan B. Vermorken. 2023. Critical Issues in Head and Neck Oncology. Critical Issues in Head and Neck Oncology
129
164
.
Kun Liu, Yang Wang, Lin Ma, Shiming Yang & Xinxin Zhang. (2022) Efficacy and safety of a treatment in patients with locoregionally advanced nasopharyngeal carcinoma (LANC) involving carotid artery invasion. European Archives of Oto-Rhino-Laryngology 279:12, pages 5791-5799.
Crossref
Crossref
Yan Yuan, Jiuzhou Chen, Miao Fang, Yaru Guo, Xueqing Sun, Dehong Yu, Yilong Guo & Yong Xin. (2022) Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials. Frontiers in Oncology 12.
Crossref
Crossref
Gabriele Hintzen, Holger J. Dulat & Erich Rajkovic. (2022) Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling. Frontiers in Oncology 12.
Crossref
Crossref
Saloni Ramani, Sayalee Samant & Sonal M Manohar. (2022) The story of EGFR: from signaling pathways to a potent anticancer target. Future Medicinal Chemistry 14:17, pages 1267-1288.
Crossref
Crossref
Yan Li, Ziyi Xu, Tongji Xie, Puyuan Xing, Jianming Ying & Junling Li. (2022) Heterogeneity of resistant mechanisms in an EGFR-TKI relapsed patient with EGFR amplification and response to nimotuzumab: A case report. Frontiers in Oncology 12.
Crossref
Crossref
Jing Hu, Zhe Chen, Jiaming Lv, Zhen Zheng, Yanping Bei, Xue Chen, Lu Zheng, Wenjie Song & Yunbao Xu. (2022) The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study. Frontiers in Oncology 12.
Crossref
Crossref
Joanna Pastwińska, Kaja Karaś, Iwona Karwaciak & Marcin Ratajewski. (2022) Targeting EGFR in melanoma – The sea of possibilities to overcome drug resistance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:4, pages 188754.
Crossref
Crossref
Zhi-Hang Xu, Wen-Quan Wang, Liang Liu & Wen-Hui Lou. (2022) A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:4, pages 188751.
Crossref
Crossref
Usha Patel, Sadhana Kannan, Swapnil U. Rane, Neha Mittal, Poonam Gera, Asawari Patil, Subhakankha Manna, Vishwayani Shejwal, Vanita Noronha, Amit Joshi, Vijay M. Patil, Kumar Prabhash & Manoj B. Mahimkar. (2022) Prognostic and predictive roles of cancer stem cell markers in head and neck squamous cell carcinoma patients receiving chemoradiotherapy with or without nimotuzumab. British Journal of Cancer 126:10, pages 1439-1449.
Crossref
Crossref
Nandini Menon, Vijay Patil, Vanita Noronha, Amit Joshi, Atanu Bhattacharjee, Balajirao J Satam, Vijayalakshmi Mathrudev, Sarbani Ghosh Laskar & Kumar Prabhash. (2021) Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone – Additional data from a phase 3 trial. Oral Oncology 122, pages 105517.
Crossref
Crossref
Phuoc Vinh Nguyen, Emilie Allard-Vannier, Igor Chourpa & Katel Hervé-Aubert. (2021) Nanomedicines functionalized with anti-EGFR ligands for active targeting in cancer therapy: Biological strategy, design and quality control. International Journal of Pharmaceutics 605, pages 120795.
Crossref
Crossref
Kyu Sic You, Yong Weon Yi, Jeonghee Cho, Jeong-Soo Park & Yeon-Sun Seong. (2021) Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. Pharmaceuticals 14:6, pages 589.
Crossref
Crossref
Olga Nigro, Claudio Chini & Ilaria Proserpio. (2021) Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future. Anti-Cancer Drugs 32:6, pages 593-601.
Crossref
Crossref
Zhonghui Liao, Feize Li, Yu Tang, Weihao Liu, Jing Gao, Tu Lan, Jijun Yang, Jiali Liao, Ning Liu & Yuanyou Yang. (2021) Preliminary in vitro comparison of 111In and 131I labeled nimotuzumabs. Journal of Radioanalytical and Nuclear Chemistry 328:2, pages 527-537.
Crossref
Crossref
Sanjoy Das, Bireswar Bhattacharya, Biplajit Das, Bibek Sinha, Taison Jamatia & Kishan Paul. (2019) Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies. Indian Journal of Surgical Oncology 12:S1, pages 34-45.
Crossref
Crossref
Yurika Sastyarina, Ade Rizqi Ridwan Firdaus, Zuhrotun Nafisah, Ari Hardianto, Muhammad Yusuf, Martalena Ramli, Abdul Mutalib & Ukun MS Soedjanaatmadja. (2021)
Modeling and Molecular Dynamic Simulation of F(ab′)
2
Fragment of Nimotuzumab for Lung Cancer Diagnostics
. Bioinformatics and Biology Insights 15, pages 117793222110021.
Crossref
Crossref
Usha Patel, Manish Pandey, Sadhana Kannan, Tanuja A. Samant, Poonam Gera, Neha Mittal, Swapnil Rane, Asawari Patil, Vanita Noronha, Amit Joshi, Vijay M. Patil, Kumar Prabhash & Manoj B. Mahimkar. (2020) Prognostic and predictive significance of nuclear HIF1α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab. British Journal of Cancer 123:12, pages 1757-1766.
Crossref
Crossref
Zhichao Xue, Vivian Wai Yan Lui, Yongshu Li, Lin Jia, Chanping You, Xin Li, Wenying Piao, Hui Yuan, Pek Lan Khong, Kwok Wai Lo, Lydia Wai Ting Cheung, Victor Ho Fan Lee, Anne Wing Mui Lee, Sai Wah Tsao & Chi Man Tsang. (2020) Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma. Journal of Experimental & Clinical Cancer Research 39:1.
Crossref
Crossref
Zhaodong Fei, Ting Xu, Mengying Li, Taojun Chen, Li Li, Xiufang Qiu & Chuanben Chen. (2020) Effectiveness and cost-effectiveness analysis of nimotuzumab for the radiotherapy of locoregionally advanced nasopharyngeal carcinoma. Radiation Oncology 15:1.
Crossref
Crossref
Xishan Chen, Renba Liang & Xiaodong Zhu. (2020) Anti-EGFR therapies in nasopharyngeal carcinoma. Biomedicine & Pharmacotherapy 131, pages 110649.
Crossref
Crossref
Soyeon Kim, Joo Won Lee & Young-Seok Park. (2020) The Application of Next-Generation Sequencing to Define Factors Related to Oral Cancer and Discover Novel Biomarkers. Life 10:10, pages 228.
Crossref
Crossref
Sitanshu S. Singh, Achyut Dahal, Leeza Shrestha & Seetharama D. Jois. (2020) Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy. Current Medicinal Chemistry 27:32, pages 5274-5316.
Crossref
Crossref
In Bok An, Mi Sun Byun, Sang In Yang, Yuri Choi, Jung Won Woo, Hak Chul Jang & Young Chul Sung. (2020)
A glycosylated
Fc
‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide
. Diabetes, Obesity and Metabolism 22:8, pages 1455-1468.
Crossref
Crossref
Wen-Qi Cai, Li-Si Zeng, Li-Feng Wang, Ying-Ying Wang, Jun-Ting Cheng, Ying Zhang, Zi-Wen Han, Yang Zhou, Shao-Li Huang, Xian-Wang Wang, Xiao-Chun Peng, Ying Xiang, Zhaowu Ma, Shu-Zhong Cui & Hong-Wu Xin. (2020) The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells. Frontiers in Oncology 10.
Crossref
Crossref
Tania Crombet Ramos, Braulio Mestre Fernández, Zaima Mazorra Herrera & Normando E. Iznaga Escobar. (2020) Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck. Frontiers in Oncology 10.
Crossref
Crossref
Laura D. Scriba, Stefan R. Bornstein, Alice Santambrogio, Gregor Mueller, Angela Huebner, Julia Hauer, Andreas Schedl, Ben Wielockx, Graeme Eisenhofer, Cynthia L. Andoniadou & Charlotte Steenblock. (2020) Cancer Stem Cells in Pheochromocytoma and Paraganglioma. Frontiers in Endocrinology 11.
Crossref
Crossref
Carmen Viada, Aliz M. Vega, Mayte Robaina, Aliuska Frías, Mabel Álvarez, Yanela Santiesteban, Yuliannis Santiesteban, Lázara García, Braulio Mestre, Marta xxx Osorio, Leslie Pérez, Amparo Macias, Tania Crombet & Mayra Ramos. (2020) Evaluation of Nimotuzumab for the treatment of head and neck cancer: Meta-analysis of controlled trials. Bionatura 5:1, pages 1056-1062.
Crossref
Crossref
Yaima Tundidor, Luis F. Ponce, Lisset Chao, Joaquín Solozábal, Michael Hust, Stefan Dübel & Gertrudis Rojas. (2020) Affinity-matured variants derived from nimotuzumab keep the original fine specificity and exhibit superior biological activity. Scientific Reports 10:1.
Crossref
Crossref
KSatish Srinivas, Raja Sundaram, CV Divyambika & Sameer Chaudhari. (2020) Nimotuzumab with intensity-modulated radiation therapy in unresectable and platinum-ineligible locally advanced head-and-neck cancer. South Asian Journal of Cancer 9:1, pages 43.
Crossref
Crossref
Yunshu Zhu, Sheng Yang, Shengyu Zhou, Jianliang Yang, Yan Qin, Lin Gui, Yuankai Shi & Xiaohui He. (2020)
Nimotuzumab plus platinum-based chemotherapy
versus
platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
. Therapeutic Advances in Medical Oncology 12, pages 175883592095373.
Crossref
Crossref
Conrad Chan, Humphrey Fonge, Karen Lam & Raymond M. Reilly. (2020) Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR. Nuclear Medicine and Biology 80-81, pages 37-44.
Crossref
Crossref
Seema Rohilla, Harish Dureja & Vinay Chawla. (2019) Cytoprotective Agents to Avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review. Current Cancer Drug Targets 19:10, pages 765-781.
Crossref
Crossref
Wang Zhi-Qiang, Mei Qi, Li Ji-Bin, You Rui, Liu You-Ping, Sun Rui, Hu Guang-Yuan, Chen Ming-Yuan & Hua Yi-Jun. (2019) The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis. BMC Cancer 19:1.
Crossref
Crossref
Lian Liu, Jili Chen, Xinjia Cai, Zhigang Yao & Junhui Huang. (2019) Progress in targeted therapeutic drugs for oral squamous cell carcinoma. Surgical Oncology 31, pages 90-97.
Crossref
Crossref
Meihan Liu, Jingzhe Zhang, Hang Dong & Wenjun Wang. (2019)
Retracted
: Nimotuzuma restrains proliferation and induces apoptosis in human osteosarcoma cells by regulation of EGFR/PI3K/AKT signal pathway
. Journal of Cellular Physiology 234:11, pages 20879-20887.
Crossref
Crossref
Sidi Li, Luyang Chen, Kai Huang, Ning Chen, Qi Zhan, Kaikai Yi, Hongzhao Qi, Chaoyong Liu, Yanli Tan, Xin Hou, Yunfeng Lu, Jin Zhao, Xubo Yuan & Chunsheng Kang. (2019) Tumor Microenvironment‐Tailored Weakly Cell‐Interacted Extracellular Delivery Platform Enables Precise Antibody Release and Function. Advanced Functional Materials 29:43.
Crossref
Crossref
Vijay Maruti Patil, Vanita Noronha, Amit Joshi, Jaiprakash Agarwal, Sarbani Ghosh‐Laskar, Ashwini Budrukkar, Vedang Murthy, Tejpal Gupta, Manoj Mahimkar, Shashikant Juvekar, Supreeta Arya, Abhishek Mahajan, Archi Agarwal, Nilendu Purandare, Venkatesh Rangarajan, Arun Balaji, Sameer Vasant Chaudhari, Shripad Banavali, Sadhana Kannan, Atanu Bhattacharjee, Anil K. D’Cruz, Pankaj Chaturvedi, Prathamesh S. Pai, Devendra Chaukar, Gouri Pantvaidya, Deepa Nair, Sudhir Nair, Anuja Deshmukh, Shivakumar Thiagarajan, Vijayalakshmi Mathrudev, Aparna Manjrekar, Sachin Dhumal, Kamesh Maske, Arti Sanjay Bhelekar, Kavita Nawale, Arun Chandrasekharan, Nikhil Pande, Alok Goel, Vikas Talreja, Vijai Simha, Sujay Srinivas, Rohit Swami, Dilip Harindran Vallathol, Hollis Dsouza, Sameer Shrirangwar, Siddharth Turkar, George Abraham, Aditi Harsh Thanky, Usha Patel, Manish Kumar Pandey & Kumar Prabhash. (2019) A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer 125:18, pages 3184-3197.
Crossref
Crossref
Linwei Mao, Jiajie Tan, Fan Wang, Yunfan Luo, Wei Liu, Fangfang Zeng, Bolong Yu, Haoran Huang, Juan Lu, Xiaohong Peng & Xiong Liu. (2019) Retrospective study comparing anti‐EGFR monoclonal antibody plus cisplatin‐based chemoradiotherapy versus chemoradiotherapy alone for stage II‐IVb nasopharyngeal carcinoma and prognostic value of EGFR and VEGF expression. Clinical Otolaryngology 44:4, pages 572-580.
Crossref
Crossref
Sheng Hu, Yi‐Xing Duan, Qiang Zhou, Yong Wang & Qiang Lu. (2019) Nimotuzumab inhibits epithelial–mesenchymal transition in prostate cancer by targeting the Akt/YB‐1/AR axis. IUBMB Life 71:7, pages 928-941.
Crossref
Crossref
Kaijie He, Jianyan Xu, Jindong Liang, Jiahua Jiang, Mi Tang, Xin Ye, Zhebin Zhang, Lei Zhang, Beibei Fu, Yan Li, Chang Bai, Lianshan Zhang & Weikang Tao. (2019) Discovery of A Novel EGFR-Targeting Antibody–Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies. Molecular Cancer Therapeutics 18:6, pages 1104-1114.
Crossref
Crossref
Hidekazu Hirano & Ken Kato. (2019) Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Japanese Journal of Clinical Oncology 49:5, pages 412-420.
Crossref
Crossref
S. Kareemaghay & M. Tavassoli. (2019) Clinical immunotherapeutic approaches for the treatment of head and neck cancer. International Journal of Oral and Maxillofacial Surgery 48:4, pages 419-436.
Crossref
Crossref
Usha Pandey, Mythili Kameswaran, Naresh Gamre & Ashutosh Dash. (2019)
Preparation of
177
Lu‐labeled Nimotuzumab for radioimmunotherapy of EGFR‐positive cancers: Comparison of DOTA and CHX‐A″‐DTPA as bifunctional chelators
. Journal of Labelled Compounds and Radiopharmaceuticals 62:4, pages 158-165.
Crossref
Crossref
Jia Shen, Tao Zhang, Zheng Cheng, Ni Zhu, Hua Wang, Li Lin, Zexia Wang, Haotian Yi & Meichun Hu. (2018) Lycorine inhibits glioblastoma multiforme growth through EGFR suppression. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Crossref
Duarte Mendes Oliveira, Katia Grillone, Chiara Mignogna, Valentina De Falco, Carmelo Laudanna, Flavia Biamonte, Rosa Locane, Francesco Corcione, Massimiliano Fabozzi, Rosario Sacco, Giuseppe Viglietto, Donatella Malanga & Antonia Rizzuto. (2018) Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Crossref
Leslie Pérez Ruiz, Manuel Miguel Collazo Herrera, Normando Iznaga Escobar, Anai García Fariñas & Osvaldo Ulises Garay. (2018) Eficiencia del nimotuzumab en la atención a pacientes con cáncer de cabeza y cuello en Cuba. PharmacoEconomics Spanish Research Articles 15:1-4, pages 13-23.
Crossref
Crossref
Addys González Palomo, Armando López Medinilla, Valeria Segatori, María del Carmen Barroso, Rances Blanco, Mariano R. Gabri, Adriana Carr Pérez & Kalet León Monzón. (2018) Synergistic potentiation of the anti-metastatic effect of anti EGFR mAb by its combination with immunotherapies targeting the ganglioside NGcGM3. Oncotarget 9:35, pages 24069-24080.
Crossref
Crossref
Mei Lin, Rui You, You-Ping Liu, Yi-Nuan Zhang, Hao-Jiong Zhang, Xiong Zou, Qi Yang, Chao-Feng Li, Yi-Jun Hua, Tao Yu, Jing-Yu Cao, Ji-Bin Li, Hao-Yuan Mo, Ling Guo, Ai-Hua Lin, Ying Sun, Chao-Nan Qian, Jun Ma, Hai-Qiang Mai & Ming-Yuan Chen. (2018) Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma. Oral Oncology 80, pages 1-8.
Crossref
Crossref
Fangzheng Wang, Chuner Jiang, Zhiming Ye, Quanquan Sun, Tongxin Liu, Min Xu, Peng Wu, Kaiyuan Shi, Bin Long, Zhenfu Fu & Yangming Jiang. (2018) Efficacy and Safety of Nimotuzumab Plus Radiotherapy With or Without Cisplatin-Based Chemotherapy in an Elderly Patient Subgroup (Aged 60 and Older) With Nasopharyngeal Carcinoma. Translational Oncology 11:2, pages 338-345.
Crossref
Crossref
Wang Fangzheng, Jiang Chuner, Ye Zhiming, Liu Tongxin, Yan Fengqin, Wang Lei, Li Bin, Hu Fujun, Chen Ming, Qin Weifeng & Fu Zhenfu. (2018) Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 26:2, pages 277-287.
Crossref
Crossref
Yanhong Yang, Wenwen Zhou, Jiandong Wu, Lixin Yao, Lei Xue, Qianyi Zhang, Zhenzhen Wang, Xiaoyu Wang, Shu Dong, Jiangman Zhao & Duanduan Yin. (2018) Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549 in�vitro. Oncology Letters.
Crossref
Crossref
Fangzheng Wang, Chuner Jiang, Zhimin Ye, Tongxin Liu, Quanquan Sun, Fengqin Yan, Weifeng Qin, Zhenfu Fu & Yangming Jiang. (2018) Treatment Outcomes of 257 Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Nimotuzumab Plus Intensity-Modulated Radiotherapy with or without Chemotherapy: A Single-Institution Experience. Translational Oncology 11:1, pages 65-73.
Crossref
Crossref
Wendy Bernhard, Ayman El-Sayed, Kris Barreto, Carolina Gonzalez, Wayne Hill, Angel Casaco Parada, Humphrey Fonge & C. Ronald Geyer. (2017)
Near infrared fluorescence imaging of EGFR expression
in vivo
using IRDye800CW-nimotuzumab
. Oncotarget 9:5, pages 6213-6227.
Crossref
Crossref
Zaima Mazorra, Lisset Chao, Anabel Lavastida, Belinda Sanchez, Mayra Ramos, Normando Iznaga & Tania Crombet. (2018) Nimotuzumab: beyond the EGFR signaling cascade inhibition. Seminars in Oncology 45:1-2, pages 18-26.
Crossref
Crossref
Eric Winquist, Chika Agbassi, Brandon M. Meyers, John Yoo & Kelvin K. W. Chan. (2017) Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review. Journal of Otolaryngology - Head & Neck Surgery 46:1.
Crossref
Crossref
Lei Du, Xin-Xin Zhang, Lin-Chun Feng, Bao-Lin Qu, Jing Chen, Jun Yang, Hai-Xia Liu, Shou-Ping Xu, Chuan-Bin Xie & Lin Ma. (2017) Propensity score matching analysis of a phase II study on simultaneous modulated accelerated radiation therapy using helical tomotherapy for nasopharyngeal carcinomas. BMC Cancer 17:1.
Crossref
Crossref
Paul A. Moore, Ross La Motte‐Mohs, Jonathan C. Li & Gurunadh R. Chichili. 2017. Protein Therapeutics. Protein Therapeutics
521
585
.
Greta Garrido, Ailem Rabasa, Cristina Garrido, Lisset Chao, Federico Garrido, Ángel M. García-Lora & Belinda Sánchez-Ramírez. (2017) Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab. Frontiers in Pharmacology 8.
Crossref
Crossref
Fangzheng Wang, Chuner Jiang, Zhimin Ye, Quanquan Sun, Tongxin Liu, Min Xu, Peng Wu, Kaiyuan Shi, Bin Long, Aizawa Rihito, Sakamoto Masoto & Zhenfu Fu. (2017) Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oncotarget 8:43, pages 75544-75556.
Crossref
Crossref
Yun Yang, Rui Guo, Xiaoting Tian, Ziheng Zhang, Pengfei Zhang, Changzheng Li & Zhiwei Feng. (2017) Synergistic anti-tumor activity of Nimotuzumab in combination with Trastuzumab in HER2-positive breast cancer. Biochemical and Biophysical Research Communications 489:4, pages 523-527.
Crossref
Crossref
Zaima Mazorra, Anabel Lavastida, Fernando Concha-Benavente, Anet Valdés, Raghvendra M. Srivastava, Tatiana M. García-Bates, Esperanza Hechavarría, Zuyen González, Amnely González, Martha Lugiollo, Iván Cuevas, Carlos Frómeta, Braulio F. Mestre, Maria C. Barroso, Tania Crombet & Robert L. Ferris. (2017) Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Frontiers in Pharmacology 8.
Crossref
Crossref
Stefanie Keller & Mirko Schmidt. (2017) EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment. International Journal of Molecular Sciences 18:6, pages 1295.
Crossref
Crossref
Abhinav Tiwari, Anson K. Abraham, John M. Harrold, Anup Zutshi & Pratap Singh. (2016) Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling. The AAPS Journal 19:2, pages 510-519.
Crossref
Crossref
Jian-feng Huang, Fu-zheng Zhang, Qin-zhou Zou, Le-yuan Zhou, Bo Yang, Jian-jun Chu, Jia-hua Yu, Hao-wen Zhang, Xiao-peng Yuan, Guo-mei Tai, Fen-ju Liu & C-M Charlie Ma. (2016) Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial. Oncotarget 8:2, pages 2457-2465.
Crossref
Crossref
K. S. Kirushna Kumar, P. Ananda Selvakumar & Krishna Kumar Rathinam. (2017) Nimotuzumab in Management of Brain Stem Glioma: A Case Report. Journal of Cancer Therapy 08:02, pages 216-224.
Crossref
Crossref
Xinghua HanNannan LuYueyin PanJianming Xu. (2017) Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer. Medical Science Monitor 23, pages 412-418.
Crossref
Crossref
Do-Hyeon Kim, Dong-Kyun Kim, Kai Zhou, Soyeon Park, Yonghoon Kwon, Min Gyu Jeong, Nam Ki Lee & Sung Ho Ryu. (2017) Single particle tracking-based reaction progress kinetic analysis reveals a series of molecular mechanisms of cetuximab-induced EGFR processes in a single living cell. Chemical Science 8:7, pages 4823-4832.
Crossref
Crossref
Amritha Suresh, Ram Bhupal Reddy, Bonney Lee James & Moni Abraham Kuriakose. 2017. Contemporary Oral Oncology. Contemporary Oral Oncology
291
316
.
Leslie Pérez Ruiz, Manuel M. Collazo Herrera, Normando Iznaga Escobar & Carmen E. Viada González. (2016) Evaluación económica del tratamiento con nimotuzumab para el cáncer de cabeza y cuello en Cuba. PharmacoEconomics Spanish Research Articles 13:4, pages 133-140.
Crossref
Crossref
Radoslaw Kwapiszewski, Sebastian D. Pawlak & Karolina Adamkiewicz. (2016) Anti-EGFR Agents: Current Status, Forecasts and Future Directions. Targeted Oncology 11:6, pages 739-752.
Crossref
Crossref
Darrin Bann, Daniel Deschler & Neerav Goyal. (2016) Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma. Cancers 8:10, pages 87.
Crossref
Crossref
Matthew Zibelman & Ranee Mehra. (2016) Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology 39:4, pages 396-406.
Crossref
Crossref
Chunzi Gao, Xianzhen Wu, Ying Yan, Lingnan Meng, Dan Shan, Ying Li & Bo Han. (2015) Sensitization of Radiation or Gemcitabine-Based Chemoradiation Therapeutic Effect by Nimotuzumab in Pancreatic Cancer Cells. Technology in Cancer Research & Treatment 15:3, pages 446-452.
Crossref
Crossref
Ji Yun Lee, Jong-Mu Sun, Sung Hee Lim, Hae Su Kim, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Bo Mi Ku, Jiae Koh, Yeon-Hee Bae, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park & Myung-Ju Ahn. (2016) A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. Clinical Cancer Research 22:9, pages 2139-2145.
Crossref
Crossref
Zhi-gang Liu, Yu Zhao, Jiao Tang, Yu-juan Zhou, Wen-juan Yang, Yan-fang Qiu & Hui Wang. (2016) Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis. Oncotarget 7:17, pages 24429-24435.
Crossref
Crossref
Yang Wang, Li Pan, Xiao‐fang Sheng, Shu Chen & Jia‐zhong Dai. (2014)
Nimotuzumab, a humanized monoclonal antibody specific for the
EGFR
, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in
C
hinese patients
. Asia-Pacific Journal of Clinical Oncology 12:1.
Crossref
Crossref
Giovanna Mirone, Stefania Perna & Gabriella Marfe. 2016. Resistance to Tyrosine Kinase Inhibitors. Resistance to Tyrosine Kinase Inhibitors
27
107
.
Petr Szturz & Jan B. Vermorken. 2016. Head and Neck Cancer. Head and Neck Cancer
711
729
.
JIN-HUA GUO, MING-QIU CHEN, CHENG CHEN, HAI-JIE LU & BEN-HUA XU. (2015) Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma. Molecular and Clinical Oncology 3:5, pages 1135-1138.
Crossref
Crossref
Mythili Kameswaran, Grace Samuel, Haladhar Dev Sarma, Swamirao N. Shinde, Ashutosh Dash & Meera Venkatesh. (2015) 131 I-Nimotuzumab – A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR. Applied Radiation and Isotopes 102, pages 98-102.
Crossref
Crossref
Jeffrey D. Kearns, Raghida Bukhalid, Mark Sevecka, Gege Tan, Nastaran Gerami-Moayed, Shannon L. Werner, Neeraj Kohli, Olga Burenkova, Callum M. Sloss, Anne M. King, Jonathan B. Fitzgerald, Ulrik B. Nielsen & Beni B. Wolf. (2015) Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic. Molecular Cancer Therapeutics 14:7, pages 1625-1636.
Crossref
Crossref
Ramaswamy Bhuvaneswari, Qin Feng Ng, Patricia S.P Thong & Khee-Chee Soo. (2015) Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model. Oncotarget 6:15, pages 13487-13505.
Crossref
Crossref
Bart E.C.G. de Goeij, David Satijn, Claudia M. Freitag, Richard Wubbolts, Wim K. Bleeker, Alisher Khasanov, Tong Zhu, Gary Chen, David Miao, Patrick H.C. van Berkel & Paul W.H.I. Parren. (2015) High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody–Drug Conjugates. Molecular Cancer Therapeutics 14:5, pages 1130-1140.
Crossref
Crossref
Katharine A.R. Price & Ezra E.W. Cohen. (2015) Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN). Oral Oncology 51:5, pages 399-408.
Crossref
Crossref
Ting Jin, Yuan Zhu, Jia-Lin Luo, Ning Zhou, De-Chuan Li, Hai-Xin Ju, Yong-Tian Fan, Yong Liu, Yu-Ping Zhu, Hai-Yang Feng & Lu-Ying Liu. (2015) Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer. International Journal of Colorectal Disease 30:3, pages 337-345.
Crossref
Crossref
Naresh Somani. (2015) Nimotuzumab with Concurrent Chemo-Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). Journal of Cancer Therapy 06:04, pages 356-361.
Crossref
Crossref
S. Trivedi, F. Concha-Benavente, R.M. Srivastava, H.B. Jie, S.P. Gibson, N.C. Schmitt & R.L. Ferris. (2015) Immune biomarkers of anti-EGFR monoclonal antibody therapy. Annals of Oncology 26:1, pages 40-47.
Crossref
Crossref
Jimson W. D’Souza, Smitha Reddy, Lisa E. Goldsmith, Irina Shchaveleva, James D. Marks, Samuel Litwin & Matthew K. Robinson. (2014) Combining Anti-ERBB3 Antibodies Specific for Domain I and Domain III Enhances the Anti-Tumor Activity over the Individual Monoclonal Antibodies. PLoS ONE 9:11, pages e112376.
Crossref
Crossref
Yang Jiang, Xi-Yuan Ge, Shu-Ming Liu, Lei Zheng, Ming-Wei Huang, Yan Shi, Jia Fu, Jian-Guo Zhang & Sheng-Lin Li. (2014) Nimotuzumab suppresses epithelial–mesenchymal transition and enhances apoptosis in low-dose UV-C treated salivary adenoid cystic carcinoma cell lines in vitro. Anti-Cancer Drugs 25:9, pages 1052-1060.
Crossref
Crossref
Joaquín Manzo-Merino, Adriana Contreras-Paredes, Elenaé Vázquez-Ulloa, Leticia Rocha-Zavaleta, Alma M. Fuentes-Gonzalez & Marcela Lizano. (2014) The Role of Signaling Pathways in Cervical Cancer and Molecular Therapeutic Targets. Archives of Medical Research 45:7, pages 525-539.
Crossref
Crossref
Tania Crombet Ramos. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1679
1694
.
Zhimin Ye, Pintong Huang, Xiaofeng Zhou, Qian Huang, Qiongge� Hu, Yongjie Shui, Li Shen, Enyin Lai & Qichun Wei. (2014) Parametric contrast‑enhanced ultrasound as an early predictor of radiation‑based therapeutic response for lymph node metastases of nasopharyngeal carcinoma. Molecular and Clinical Oncology.
Crossref
Crossref
Roger B. Cohen. (2014) Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treatment Reviews 40:4, pages 567-577.
Crossref
Crossref
Manjari Pandey & Daruka Mahadevan. (2014) Monoclonal antibodies as therapeutics in human malignancies. Future Oncology 10:4, pages 609-636.
Crossref
Crossref
Giuseppe TridenteGiuseppe Tridente. 2014. Adverse Events with Biomedicines. Adverse Events with Biomedicines
277
280
.
Antonio Gualberto. 2015. Molecular Oncology. Molecular Oncology
854
860
.
Maria Teresa Solomón, Julio César Selva, Javier Figueredo, José Vaquer, Carolina Toledo, Nelson Quintanal, Silvia Salva, Rafael Domíngez, José Alert, Jorge Juan Marinello, Mauricio Catalá, Martha González Griego, Juan Antonio Martell, Patricia Lorenzo Luaces, Javier Ballesteros, Niurys de-Castro, Ferdinand Bach & Tania Crombet. (2013) Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer 13:1.
Crossref
Crossref
Yi Huang, Tao Yu, Xiaoyue Fu, Jiao Chen, Ying Liu, Chunjie Li, Yichao Xia, Zhuoyuan Zhang & Longjiang Li. (2013) EGFR inhibition prevents in vitro tumor growth of salivary adenoid cystic carcinoma. BMC Cell Biology 14:1.
Crossref
Crossref
Yuan-yuan Qu, Song-liu Hu, Xiang-ying Xu, Rui-zhi Wang, Hong-yang Yu, Jian-yu Xu, Lin Chen & Guang-lu Dong. (2013) Nimotuzumab Enhances the Radiosensitivity of Cancer Cells In Vitro by Inhibiting Radiation-Induced DNA Damage Repair. PLoS ONE 8:8, pages e70727.
Crossref
Crossref
Jan B VermorkenPol Specenier. 2013. Monoclonal Antibodies Targeting EGFR/HER2 and Clinical Outcomes in Cancer Treatment. Monoclonal Antibodies Targeting EGFR/HER2 and Clinical Outcomes in Cancer Treatment
72
89
.
Pavel Barta, Alice Laznickova, Milan Laznicek, Denis Rolando Beckford Vera & Milos Beran. (2013) Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor. Journal of Labelled Compounds and Radiopharmaceuticals 56:5, pages 280-288.
Crossref
Crossref
Kelly Dorsey & Mark Agulnik. (2013) Promising New Molecular Targeted Therapies in Head and Neck Cancer. Drugs 73:4, pages 315-325.
Crossref
Crossref
Meilyn Rodríguez, Lincidio Pérez, Jorge V. Gavilondo, Greta Garrido, Mónica Bequet‐Romero, Ignacio Hernández, Vivian Huerta, Gleysin Cabrera, Marlene Pérez, Osmani Ramos, René Leyva, Mariela León, Pedro Luis Ramos, Ada Triguero, Abel Hernández, Belinda Sánchez, Marta Ayala, Jeny Soto, Ernesto González, Osmani Mendoza, Kenia Tiel & Merardo Pujol. (2012)
Comparative
in vitro
and experimental
in vivo
studies of the anti–epidermal growth factor receptor antibody nimotuzumab and its aglycosylated form produced in transgenic tobacco plants
. Plant Biotechnology Journal 11:1, pages 53-65.
Crossref
Crossref
Mark Agulnik. (2012) New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Medical Oncology 29:4, pages 2481-2491.
Crossref
Crossref
Senxiang YanXue JiangJinsong YangDanfang YanYi-Xiang J. Wang. (2012) Radiotherapy for Nasopharyngeal Carcinoma and Combined Capecitabine and Nimotuzumab Treatment for Lung Metastases in a Liver Transplantation Recipient: A Case Experience of Sustained Complete Response. Cancer Biotherapy and Radiopharmaceuticals 27:8, pages 519-523.
Crossref
Crossref
Roshan James, Siddharth Vishwakarma, Indira V. Chivukula, Chetana Basavaraj, Ramakrishnan Melarkode, Enrique Montero & Pradip Nair. (2012)
EGFR
targeting monoclonal antibody combines with an
mTOR
inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs
. Cancer Medicine 1:2, pages 114-127.
Crossref
Crossref
Janice M. Reichert & Eugen Dhimolea. (2012) The future of antibodies as cancer drugs. Drug Discovery Today 17:17-18, pages 954-963.
Crossref
Crossref
Kuai-le Zhao, Xi-chun Hu, Xiang-hua Wu, Xiao-long Fu, Min Fan & Guo-Liang Jiang. (2011) A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus. Investigational New Drugs 30:4, pages 1585-1590.
Crossref
Crossref
Chengyuan Ma, Yang Li, Zhixin Li, Haiyan Huang, Kan Xu, Haiyang Xu, Jieying Bai, Xiao Li & Gang Zhao. (2012) Synthesis and purification of a toxin-linked conjugate targeting epidermal growth factor receptor in Escherichia coli. Protein Expression and Purification 83:1, pages 1-7.
Crossref
Crossref
Shoude Zhang, Jia Chen, Hua Jiang, Haina Ma & Beibei Yang. (2012) Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis. European Journal of Clinical Pharmacology 68:5, pages 561-569.
Crossref
Crossref
O. L. Polanovski, E. N. Lebedenko & S. M. Deyev. (2012) ERBB oncogene proteins as targets for monoclonal antibodies. Biochemistry (Moscow) 77:3, pages 227-245.
Crossref
Crossref
Denis R. Beckford Vera, Sebastian Eigner, Katerina Eigner Henke, Ondrej Lebeda, Frantisek Melichar & Milos Beran. (2012) Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors. Nuclear Medicine and Biology 39:1, pages 3-13.
Crossref
Crossref
Yan Michael Li & Walter A Hall. (2011) Cell Surface Receptors in Malignant Glioma. Neurosurgery 69:4, pages 980-994.
Crossref
Crossref
Arlhee Diaz & Kalet Leon. (2011) Therapeutic Approaches to Target Cancer Stem Cells. Cancers 3:3, pages 3331-3352.
Crossref
Crossref
Denis Rolando Beckford VeraSebastian EignerMilos BeranKaterina Eigner HenkeAlice LaznickovaMilan LaznicekFrantisek MelicharMarco Chinol. (2011)
Preclinical Evaluation of
177
Lu-Nimotuzumab: A Potential Tool for Radioimmunotherapy of Epidermal Growth Factor Receptor–Overexpressing Tumors
. Cancer Biotherapy and Radiopharmaceuticals 26:3, pages 287-297.
Crossref
Crossref
Ren-Yuan Bai, Verena Staedtke & Gregory J. Riggins. (2011) Molecular targeting of glioblastoma: Drug discovery and therapies. Trends in Molecular Medicine 17:6, pages 301-312.
Crossref
Crossref
Rolando Perez, Ernesto Moreno, Greta Garrido & Tania Crombet. (2011) EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab’s Clinical Effects. Cancers 3:2, pages 2014-2031.
Crossref
Crossref
Agustin Lage & Tania Crombet. (2011) Control of Advanced Cancer: The Road to Chronicity. International Journal of Environmental Research and Public Health 8:3, pages 683-697.
Crossref
Crossref
Hyunbo Shim. (2011) One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Experimental and Molecular Medicine 43:10, pages 539.
Crossref
Crossref
Jan B. Vermorken. 2011. Head and Neck Cancer. Head and Neck Cancer
651
664
.
J.B. Vermorken & P. Specenier. (2010) Optimal treatment for recurrent/metastatic head and neck cancer. Annals of Oncology 21, pages vii252-vii261.
Crossref
Crossref
François Ehrenmann, Quentin Kaas & Marie-Paule Lefranc. (2010) IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF. Nucleic Acids Research 38:suppl_1, pages D301-D307.
Crossref
Crossref